Cargando…

PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure

BACKGROUND: Treatment options for radio-recurrent prostate cancer are either androgen-deprivation therapy or salvage prostatectomy. Whole-gland high-intensity focussed ultrasound (HIFU) might have a role in this setting. METHODS: An independent HIFU registry collated consecutive cases of HIFU. Betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, T T, Peters, M, Kanthabalan, A, McCartan, N, Fatola, Y, van der Voort van Zyp, J, van Vulpen, M, Freeman, A, Moore, C M, Arya, M, Emberton, M, Ahmed, H U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983180/ https://www.ncbi.nlm.nih.gov/pubmed/27431499 http://dx.doi.org/10.1038/pcan.2016.23

Ejemplares similares

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Focal HIFU therapy for anterior compared to posterior prostate cancer lesions
por: Huber, Philipp M., et al.
Publicado: (2020)

Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review
por: Duijzentkunst, D. A. Smit, et al.
Publicado: (2016)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Comparative cost-effectiveness of focal and total salvage (125)I brachytherapy for recurrent prostate cancer after primary radiotherapy
por: Peters, Max, et al.
Publicado: (2016)

Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
por: Maenhout, Metha, et al.
Publicado: (2017)

Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival
por: Freiberger, Carla, et al.
Publicado: (2017)

Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?
por: Rakauskas, Arnas, et al.
Publicado: (2021)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives
por: van Son, Marieke, et al.
Publicado: (2018)

Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient’s perspective
por: van Son, Marieke, et al.
Publicado: (2020)

The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy
por: Simmons, Lucy A M, et al.
Publicado: (2017)

Oral squamous cell carcinoma involving the maxillae: Factors affecting local recurrence and the value of salvage treatment for overall survival
por: Slieker, Fons J. B., et al.
Publicado: (2020)

Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer
por: Maenhout, Metha, et al.
Publicado: (2017)

Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery
por: Lee, Jun Hee, et al.
Publicado: (2015)

TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study
por: Zhang, Qiwei, et al.
Publicado: (2021)

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’
por: Ahmed, Kamran A, et al.
Publicado: (2014)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap
por: Franca, Carlos Antônio da Silva, et al.
Publicado: (2014)

Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients
por: van Son, Marieke, et al.
Publicado: (2020)

Experimental study of beam distortion due to fiducial markers during salvage HIFU in the prostate
por: Bakaric, Marina, et al.
Publicado: (2018)

Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
por: Hakozaki, Yuji, et al.
Publicado: (2023)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer
por: Van Son, Marieke J, et al.
Publicado: (2018)

Durable Control and Overall Survival Benefit with Focal Reirradiation in Cervical Cancer
por: Amini, Arya, et al.
Publicado: (2015)

A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
por: Guillaumier, Stephanie, et al.
Publicado: (2018)

A Systematic Review on Overall Survival and Disease-Free Survival Following Total Pelvic Exenteration
por: Miri, Seyed Rouhollah, et al.
Publicado: (2022)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Posttreatment M‐Protein Nadir Level Is a Significant Prognostic Factor Associated with Survival in Multiple Myeloma
por: Shimizu, Kazuyuki, et al.
Publicado: (1999)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Mental Health in Northern Ireland—Laws Ancient and Modern
por: McCartan, William
Publicado: (1963)

Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study
por: van der Horst, Chiel A. J., et al.
Publicado: (2022)

Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models
por: Stavrinides, Vasilis, et al.
Publicado: (2021)

Prediction of overall survival following colorectal cancer surgery in elderly patients
por: Seow-En, Isaac, et al.
Publicado: (2019)

What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer?
por: Milecki, Piotr, et al.
Publicado: (2011)

Feasibility of volumetric MRI-guided high intensity focused ultrasound (MR-HIFU) for painful bone metastases
por: Huisman, Merel, et al.
Publicado: (2014)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9q4bia6ljktqnm9lo82ei5trr6